A new study confirms that G207, a genetically engineered virus developed at UAB, may be a beneficial therapy for brain tumors.
A detailed mechanistic study unravels how the bacterial endotoxin LPS prevents or promotes allergic disease.
Disruption of Blimp1 in regulatory T cells remodels the tumor microenvironment and augments the response to immunotherapy.
Although unproven, this novel sickle cell therapy serves as a potential cure. More measures need to be taken to determine long-term function and organ improvement.
At UAB, the company IN8bio Inc. is running a Phase I clinical trial to treat glioblastoma multiforme, the most aggressive type of cancer that originates in the brain.
The PPMI study is looking for biomarkers for Parkinson’s disease, which would help identify those at risk and track the progression of the disease.
UAB O’Neal Comprehensive Cancer Center, Morehouse School of Medicine and Tuskegee University collectively receive $18 million U54 grant from the National Cancer Institute.
After years of researching the SON gene, Erin Eun-Young Ahn, Ph.D., may have found the cause behind an extremely rare disease.
Recent studies have shown that formal exercise training can help boost memory, and memory deficit is relatively common in people with epilepsy.
COERE awarded $500,000 to provide funds for research supplements to early-career physician-scientists whose research has been impacted by COVID-19.
Basic and translational research in this field aims to repair heart injury and prevent the heart failure that often follows a heart attack.
Nearly 100,000 people in the United States have AE-IPF, and approximately 30,000 to 40,000 new cases are found each year.
